Enanta Pharmaceuticals | ENTA - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Amgen USD 5.14B 775M 2025-12
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD 64.2M 223.53M 2025-09
AstraZeneca USD 5.67B 1.29B 2026-03
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Biogen USD 649.7M 76.5M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Halozyme Therapeutics USD 21.9M 226.34M 2025-12
Heron Therapeutics USD -3.88M 5.63M 2024-09
Immunic USD -22.78M 753K 2024-06
Incyte USD 367.97M 46.53M 2026-03
Insmed USD -314.19M 31.48M 2025-12
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
J&J USD 7.19B 2.32B 2025-12
Karyopharm Therapeutics USD -26.2M 1.83M 2024-09
Ligand Pharmaceuticals USD 150.32M 129.42M 2025-09
Merck USD 6.3B 2.09B 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 5.3B 530M 2026-03
Novavax USD 19.36M 190.79M 2025-12
Pfizer USD 756M 5.32B 2025-12
PTC Therapeutics USD -70.99M 91.62M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Vertex Pharmaceuticals USD 1.39B 48.8M 2025-12